@article{c78624dd86e24fbeab9501d4023b2542,
title = "Modeling residential indoor concentrations of PM2.5, NO2, NOx, and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study",
abstract = "Increased outdoor concentrations of fine particulate matter (PM2.5) and oxides of nitrogen (NO2, NOx) are associated with respiratory and cardiovascular morbidity in adults and children. However, people spend most of their time indoors and this is particularly true for individuals with chronic obstructive pulmonary disease (COPD). Both outdoor and indoor air pollution may accelerate lung function loss in individuals with COPD, but it is not feasible to measure indoor pollutant concentrations in all participants in large cohort studies. We aimed to understand indoor exposures in a cohort of adults (SPIROMICS Air, the SubPopulations and Intermediate Outcome Measures in COPD Study of Air pollution). We developed models for the entire cohort based on monitoring in a subset of homes, to predict mean 2-week–measured concentrations of PM2.5, NO2, NOx, and nicotine, using home and behavioral questionnaire responses available in the full cohort. Models incorporating socioeconomic, meteorological, behavioral, and residential information together explained about 60% of the variation in indoor concentration of each pollutant. Cross-validated R2 for best indoor prediction models ranged from 0.43 (NOx) to 0.51 (NO2). Models based on questionnaire responses and estimated outdoor concentrations successfully explained most variation in indoor PM2.5, NO2, NOx, and nicotine concentrations.",
keywords = "air pollutants, exposure assessment, indoor exposure questionnaires, indoor monitoring, prediction modeling, residential behavior",
author = "Marina Zusman and Gassett, {Amanda J.} and Kipruto Kirwa and Barr, {R. Graham} and Cooper, {Christopher B.} and Han, {Mei Lan K.} and Kanner, {Richard E.} and Kirsten Koehler and Ortega, {Victor E.} and Robert Paine and Laura Paulin and Cheryl Pirozzi and Ana Rule and Hansel, {Nadia N.} and Kaufman, {Joel D.}",
note = "Funding Information: This publication was developed under the SPIROMICS Air study that was supported by NIH NIEHS (R01ES023500). This project was also supported by NIH/NIEHS grants K23ES025781 and P30ES007033. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C) and grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc; GlaxoSmithKline; Grifols Therapeutics, Inc; Ikaria, Inc; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan. The MESA Air study was developed under a STAR research assistance agreement, No. RD831697 (MESA Air) and RD83830001 (MESA Air Next Stage), awarded by the US Environmental Protection Agency. It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors, and the EPA does not endorse any products or commercial services mentioned in this publication. The authors would like to thank the participants and investigators of the SPIROMICS and SPIROMICS Air studies for their critical contributions, with additional gratitude for the assistance from the staff at the Winston‐Salem, Ann Arbor, San Francisco, Los Angeles, New York City, Salt Lake City, and Baltimore clinical centers. Funding Information: This publication was developed under the SPIROMICS Air study that was supported by NIH NIEHS (R01ES023500). This project was also supported by NIH/NIEHS grants K23ES025781 and P30ES007033. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C) and grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc; GlaxoSmithKline; Grifols Therapeutics, Inc; Ikaria, Inc; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan. The MESA Air study was developed under a STAR research assistance agreement, No. RD831697 (MESA Air) and RD83830001 (MESA Air Next Stage), awarded by the US Environmental Protection Agency. It has not been formally reviewed by the?EPA. The views expressed in this document are solely those of the authors, and?the EPA does not endorse any products or commercial services mentioned in this publication. The authors would like to thank the participants and investigators of the SPIROMICS and SPIROMICS Air studies for their critical contributions, with additional gratitude for the assistance from the staff at the Winston-Salem, Ann Arbor, San Francisco, Los Angeles, New York City, Salt Lake City, and Baltimore clinical centers. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2021",
month = may,
doi = "10.1111/ina.12760",
language = "English (US)",
volume = "31",
pages = "702--716",
journal = "Indoor Air",
issn = "0905-6947",
publisher = "Blackwell Munksgaard",
number = "3",
}